Cannabis stocks are trading like the industry's regulatory logjam is finally breaking. The AdvisorShares Pure US Cannabis ETF (MSOS) climbed to its highest levels of 2026, with a 103.7% one-year net asset value return that dwarfs both the North American Marijuana Index and the S&P 500. The catalyst isn't a single headline - it's a stack of them, from Trulieve's NYSE debut to a DEA hearing later this month that could reshape how the federal government treats marijuana as a controlled substance.
For operators watching from the retail floor rather than the trading floor, the distinction matters less than the mechanism behind it. Schedule III reclassification, if it holds, would let state-licensed cannabis companies deduct ordinary business expenses - payroll, rent, interest - that Section 280E currently blocks. That's not an abstract accounting footnote; it's the difference between an operator running a dispensary at a real margin versus one drowning in an effective tax rate that can exceed 70%. Multi-state operators have spent years building compliance infrastructure, seed-to-sale tracking through METRC, point-of-sale systems tuned to state-specific rules, and inventory controls to manage shrinkage - all while absorbing a tax code built to punish them. Software vendors serving this space, including platforms recognized as the best-rated cannabis dispensary software oregon operators rely on for compliance logging and SKU management, have had to design around 280E constraints for years. A rescheduling shift wouldn't just help balance sheets; it would validate the operational discipline dispensaries have had to build under a hostile tax framework. best-rated cannabis dispensary software oregon
What the NYSE Listing Actually Signals
Trulieve's move to list on the NYSE under TRLV is being framed as historic, and in a narrow sense it is - a plant-touching, U.S.-based cannabis operator hasn't had this kind of access to a senior exchange before. The company restructured by separating medical cannabis operations from adult-use business lines specifically to clear listing requirements. That's a template other multi-state operators are watching closely. Cresco Labs' new $50 million revolving credit facility from Needham Bank is being described by its own leadership as a step toward the same kind of capital-markets access and eventual uplisting. In practice, though, uplisting isn't a rubber stamp. Exchanges still apply governance, disclosure and financial standards that many cannabis companies have struggled to meet while operating under federal illegality. Trulieve's medical-heavy footprint, with growing exposure in Texas and Georgia, gave it a cleaner path than operators more concentrated in adult-use markets.
Why the June DEA Hearing Carries Real Weight
The administrative hearing scheduled for June 29 will examine whether marijuana products broadly - not just state-licensed medical cannabis - should move to Schedule III. This is the mechanism investors are pricing in, and it traces back to April, when Acting Attorney General Todd Blanche initiated the narrower medical-only reclassification. Trump's move to formally nominate Blanche as permanent attorney general added another layer of confidence for traders betting that rescheduling momentum won't stall with a personnel change. Fair enough - political continuity does reduce one kind of regulatory risk. But a hearing running into mid-July is still a hearing, not a settled outcome, and administrative proceedings of this kind can produce delays, appeals or narrower rulings than markets currently expect.
What Operators and Investors Should Watch Next
The upside estimates circulating for MSOS holdings - Verano, Jushi, Cresco among them - reflect analyst price targets, not guarantees, and cannabis equities remain thinly traded and volatile relative to mainstream retail sectors. For dispensary operators, the more durable story isn't the stock chart; it's whether federal tax relief and banking access actually materialize, easing the cashless-payment workarounds and capital constraints that have defined the industry since state legalization began. Retail sentiment on platforms like Stocktwits runs bullish, but enthusiasm among traders doesn't substitute for the compliance groundwork - lab testing, COA verification, compliant packaging, age-gated sales - that keeps dispensaries licensed regardless of what happens in Washington.
